Anixa Biosciences, Inc. (ANIX)
NASDAQ: ANIX · Real-Time Price · USD
2.440
-0.160 (-6.15%)
Nov 20, 2026, 4:00 PM EST - Market closed
Anixa Biosciences Market Cap
Anixa Biosciences has a market cap or net worth of $84.82 million as of November 20, 2026. It is the 25,690th most valuable company in the world and the 4,111th biggest in the United States. Its market cap has decreased by 40.77% in one year.
Market Cap
84.82M
Enterprise Value
71.13M
1-Year Change
-40.77%
Global Rank
Country Rank
#4,111 United States
Category
ChartMarket Cap Chart
Since December 1, 1998, Anixa Biosciences's market cap has increased from $83.20M to $84.82M, an increase of 1.95%. That is a compound annual growth rate of 0.07%.
| Date | Market Cap | % Change |
|---|---|---|
| Nov 20, 2026 | 84.80M | -17.43% |
| Dec 31, 2025 | 102.70M | 37.48% |
| Dec 31, 2024 | 74.70M | -38.06% |
| Dec 29, 2023 | 120.60M | -7.44% |
| Dec 30, 2022 | 130.30M | 46.40% |
| Dec 31, 2021 | 89.00M | 21.92% |
| Dec 31, 2020 | 73.00M | 10.11% |
| Dec 31, 2019 | 66.30M | -10.04% |
| Dec 31, 2018 | 73.70M | 106.44% |
| Dec 29, 2017 | 35.70M | -24.52% |
| Dec 30, 2016 | 47.30M | 79.85% |
| Dec 31, 2015 | 26.30M | 10.04% |
| Dec 31, 2014 | 23.90M | -39.34% |
| Dec 31, 2013 | 39.40M | 18.32% |
| Dec 31, 2012 | 33.30M | 73.44% |
| Dec 30, 2011 | 19.20M | -39.81% |
| Dec 31, 2010 | 31.90M | -65.14% |
| Dec 31, 2009 | 91.50M | 61.95% |
| Dec 31, 2008 | 56.50M | -63.00% |
| Dec 31, 2007 | 152.70M | 62.27% |
| Dec 29, 2006 | 94.10M | 31.24% |
| Dec 30, 2005 | 71.70M | -0.42% |
| Dec 31, 2004 | 72.00M | 94.07% |
| Dec 31, 2003 | 37.10M | 183.21% |
| Dec 31, 2002 | 13.10M | -52.88% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Zura Bio | 89.63M |
| Molecular Partners AG | 88.72M |
| Retension Pharmaceuticals | 87.57M |
| NeOnc Technologies Holdings | 87.48M |
| Equillium | 87.26M |
| Upstream Bio | 87.15M |
| Innate Pharma | 85.43M |
| Rallybio | 83.29M |